Overview
Combivent Respimat is a prescription drug approved by the Food and Drug Administration (FDA) in 2011 to prevent bronchospasm in people with chronic obstructive pulmonary disease (COPD). Combivent Respimat is prescribed in cases where people with COPD are using an aerosol inhaler but still experiencing bronchospasms.

Combivent Respimat is a combination drug containing both Ipratropium bromide and Albuterol. Both Ipratropium bromide and Albuterol are short-acting bronchodilators. Bronchodilators are drugs that dilate the bronchi and bronchioles in the lungs, making it easier to breathe. Combivent Respimat is believed to work by relaxing smooth muscles in the airways.
... read more

Combivent Respimat (Ipratropium bromide/Albuterol) Questions

MyCOPDTeam is a free social network that makes it easy to find others like you and gain insights from others living with COPD.
Sign up Log in